Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 5, 2003BloodOpen Access

Neonatal or hepatocyte growth factor–potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B

View Full Paper
Ask AI
Bookmark
Share

Authors

LXLingfei XuWashington University in St. LouisCGCuihua GaoAstraZeneca (United States)MSMark S. SandsWashington University in St. Louis

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xu et al. (2003) studied this question.

synapsesocial.com/papers/6a1219668edbaba0bf66a6cbhttps://doi.org/10.1182/blood-2002-10-3050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hematology: Basic Principles and Practice1991 · 1,865 citations
  2. 2A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B1997 · 291 citations
  3. 3Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy2002 · 338 citations
  4. 4Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA2001 · 151 citations